http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2514638-C1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_314ceac477d91a62d862e66a925502ce
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
filingDate 2013-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2014-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7b1902fdffaec344b6f15ffb94cf1aa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0790b99e3899508bbbb166e5b20497b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_87e88a78472e746809c9a4b02cc0de50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bbd3a78193a6a36b7dc3b75100ec0d34
publicationDate 2014-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2514638-C1
titleOfInvention Method of treating visual organ lymphomas
abstract FIELD: medicine. n SUBSTANCE: method provides conducting a radiation therapy to a total boost dose of 30-40 Gy. 60-90 Minutes before each session of the radiation therapy, 1% emoxipin is instilled 1-2 drops every 4-6 minutes for 30-40 minutes. The radiation session is immediately preceded by instillations of Coletex-gel-DNA-L hydrogel pre-dissolved in ratio 2:1 with an artificial tear preparation, 1-2 drops. Before bedtime, Coletex-gel-DNA hydrogel dissolved similarly is instilled in the same dose of 1-2 drops. After the radiation is completed, Coletex-gel-DNA hydrogel is instilled 2 times a day every 10-12 hours for 6-10 days. n EFFECT: method enables providing higher clinical effectiveness ensured by improving the protection of an anterior segment of the eyeball, reducing a degree of manifestation of radioreactions in a combination with a possibility to increase a total boost dose with no break in treatment. n 4 ex
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2612006-C1
priorityDate 2013-01-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2367388-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2347591-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012149678-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID379849
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419497675
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID379849
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID114681

Total number of triples: 26.